Nobumasa Okumura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nobumasa Okumura has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Norio Ohmagari
Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
15 shared publications- Mugen Ujiie
Disease Control and Prevention Center, Japan Institute of Health Security, Tokyo, Japan
8 shared publications - Naoya Itoh
Department of Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University
7 shared publications - Kei Yamamoto
Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute of Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
6 shared publications - Norio Ohmagari
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
6 shared publications - Sho Saito
Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Shinjuku, Tokyo, Japan
6 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e255
Impact of an eConsult-based antimicrobial stewardship program using the ExpertTWIN system: a Bayesian structural time-series analysis
Objective: Antimicrobial stewardship programs (ASPs) are difficult to implement in hospitals with limited access to infectious disease (ID) specialists. Electronic consultation–based tele-stewardship may offer a scalable solution; however, evidence regarding its implementation and impact remains limited. This study evaluated the impact of an eConsult-based remote antimicrobial stewardship program on antimicrobial consumption and resistance patterns. Design: Single-center retrospective observational study. Setting: A 500-bed tertiary care hospital without on-site ID specialists. Patients: In total, 27,863 patients were hospitalized. Interventions: An asynchronous eConsult-based tele-stewardship program using the ExpertTWIN system was implemented in February 2025. Data from February 2024 to January 2026 were analyzed using a Bayesian structural time-series model. Results: During the intervention period, 145 cases were reviewed. Carbapenem use decreased; use of antipseudomonal and narrow-spectrum agents showed evidence of increases, whereas use of anti-MRSA agents and total oral and intravenous antimicrobial use showed evidence of reductions. The incidences of carbapenem-resistant Pseudomonas aeruginosa , two-drug-resistant P. aeruginosa , and MRSA showed evidence of reductions, whereas third-generation cephalosporin-resistant Escherichia coli increased. Culture specimen submission showed evidence of an increase. There was no clear evidence of reductions in all-cause in-hospital mortality or length of stay. Total antimicrobial costs were unchanged. Conclusions: The eConsult-based tele-stewardship program reduced carbapenem use and was associated with favorable changes in several antimicrobial-use, resistance, and diagnostic measures, although third-generation cephalosporin-resistant E. coli increased. No clear changes in clinical outcomes were observed. This model may offer a practical and scalable ASP strategy for hospitals without on-site ID specialists.
- 7 September 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e255
Open AccessImpact of an eConsult-based antimicrobial stewardship program using the ExpertTWIN system: a Bayesian structural time-series analysis
Objective: Antimicrobial stewardship programs (ASPs) are difficult to implement in hospitals with limited access to infectious disease (ID) specialists. Electronic consultation–based tele-stewardship may offer a scalable solution; however, evidence regarding its implementation and impact remains limited. This study evaluated the impact of an eConsult-based remote antimicrobial stewardship program on antimicrobial consumption and resistance patterns. Design: Single-center retrospective observational study. Setting: A 500-bed tertiary care hospital without on-site ID specialists. Patients: In total, 27,863 patients were hospitalized. Interventions: An asynchronous eConsult-based tele-stewardship program using the ExpertTWIN system was implemented in February 2025. Data from February 2024 to January 2026 were analyzed using a Bayesian structural time-series model. Results: During the intervention period, 145 cases were reviewed. Carbapenem use decreased; use of antipseudomonal and narrow-spectrum agents showed evidence of increases, whereas use of anti-MRSA agents and total oral and intravenous antimicrobial use showed evidence of reductions. The incidences of carbapenem-resistant Pseudomonas aeruginosa , two-drug-resistant P. aeruginosa , and MRSA showed evidence of reductions, whereas third-generation cephalosporin-resistant Escherichia coli increased. Culture specimen submission showed evidence of an increase. There was no clear evidence of reductions in all-cause in-hospital mortality or length of stay. Total antimicrobial costs were unchanged. Conclusions: The eConsult-based tele-stewardship program reduced carbapenem use and was associated with favorable changes in several antimicrobial-use, resistance, and diagnostic measures, although third-generation cephalosporin-resistant E. coli increased. No clear changes in clinical outcomes were observed. This model may offer a practical and scalable ASP strategy for hospitals without on-site ID specialists.
- Open Access
- 15 February 2026
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 65 (4) , 615-620
Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
We herein report a case of disseminated strongyloidiasis in a 64-year-old man with human T-lymphotropic virus type 1 (HTLV-1) infection who developed the condition after undergoing chemoradiotherapy for lung cancer. Treatment included daily ivermectin, which eradicated Strongyloides stercoralis after 7 days but was interrupted after 14 days due to the development of skin rashes. After excluding ivermectin as the cause of the drug eruption, intermittent ivermectin was continued monthly for six months, with no recurrence of strongyloidiasis or bacteremia. This case highlights the importance of obtaining a comprehensive patient history and making an early diagnosis to improve the outcomes of disseminated strongyloidiasis.
- 15 February 2026
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 65 (4) , 615-620
Open AccessDisseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
We herein report a case of disseminated strongyloidiasis in a 64-year-old man with human T-lymphotropic virus type 1 (HTLV-1) infection who developed the condition after undergoing chemoradiotherapy for lung cancer. Treatment included daily ivermectin, which eradicated Strongyloides stercoralis after 7 days but was interrupted after 14 days due to the development of skin rashes. After excluding ivermectin as the cause of the drug eruption, intermittent ivermectin was continued monthly for six months, with no recurrence of strongyloidiasis or bacteremia. This case highlights the importance of obtaining a comprehensive patient history and making an early diagnosis to improve the outcomes of disseminated strongyloidiasis.
- Open Access
- 28 November 2025
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 78 (6) , 223-227
Antimicrobial Susceptibility and Clinical Phenotypes of Staphylococcus argenteus Isolated from Clinical Specimens
Recently, Staphylococcus argenteus, previously indistinguishable from Staphylococcus aureus, has been recognized as a clinically relevant microorganism because of mass spectrometry. However, despite its clinical significance, limited information is available on S. argenteus. This study evaluated the antimicrobial susceptibility and clinical phenotypes of S. argenteus isolated from clinical specimens. This single-center, retrospective study analyzed cases wherein S. argenteus was detected in clinical specimens obtained at Nagoya City University East Medical Center between April 2023 and April 2024. The organism was identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Patient data, including clinical outcomes, were collected and reviewed to classify cases as infections or colonization. S. argenteus was isolated from 23 specimens of 21 patients, with sputum being the most common source (78.3%). Sixty-seven percent of isolates were susceptible to penicillin; 95.2% to erythromycin; and 100% to oxacillin, clindamycin, sulfamethoxazole-trimethoprim, vancomycin, and teicoplanin. Thirteen cases of infection were recorded; pneumonia was the predominant diagnosis (11 cases) in these cases, followed by otitis externa and vertebral osteomyelitis. Most patients were successfully treated with antibiotics, and only one died of S. argenteus pneumonia.
- 28 November 2025
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 78 (6) , 223-227
Open AccessAntimicrobial Susceptibility and Clinical Phenotypes of Staphylococcus argenteus Isolated from Clinical Specimens
Recently, Staphylococcus argenteus, previously indistinguishable from Staphylococcus aureus, has been recognized as a clinically relevant microorganism because of mass spectrometry. However, despite its clinical significance, limited information is available on S. argenteus. This study evaluated the antimicrobial susceptibility and clinical phenotypes of S. argenteus isolated from clinical specimens. This single-center, retrospective study analyzed cases wherein S. argenteus was detected in clinical specimens obtained at Nagoya City University East Medical Center between April 2023 and April 2024. The organism was identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Patient data, including clinical outcomes, were collected and reviewed to classify cases as infections or colonization. S. argenteus was isolated from 23 specimens of 21 patients, with sputum being the most common source (78.3%). Sixty-seven percent of isolates were susceptible to penicillin; 95.2% to erythromycin; and 100% to oxacillin, clindamycin, sulfamethoxazole-trimethoprim, vancomycin, and teicoplanin. Thirteen cases of infection were recorded; pneumonia was the predominant diagnosis (11 cases) in these cases, followed by otitis externa and vertebral osteomyelitis. Most patients were successfully treated with antibiotics, and only one died of S. argenteus pneumonia.
- 23 September 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (10) , 102813
Cellulitis with bacteremia caused by Pseudomonas mosselii in a Japanese patient: A case report
- 23 September 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (10) , 102813
Cellulitis with bacteremia caused by Pseudomonas mosselii in a Japanese patient: A case report
- 24 July 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (9) , 102775
Effectiveness of intramuscular spectinomycin in difficult-to-treat Mycoplasma genitalium urethritis in four cases
- 24 July 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (9) , 102775
Effectiveness of intramuscular spectinomycin in difficult-to-treat Mycoplasma genitalium urethritis in four cases
- 25 February 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (4) , 102664
Impact of BD BACTEC blood culture bottle shortage on performance metrics: An interrupted time-series analysis at a Japanese university-affiliated hospital
- 25 February 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (4) , 102664
Impact of BD BACTEC blood culture bottle shortage on performance metrics: An interrupted time-series analysis at a Japanese university-affiliated hospital
- 21 February 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
Background: This randomized controlled trial provided LC16m8 pre-exposure prophylaxis to high-risk individuals to assess its efficacy for mpox prevention, safety, and immunogenicity. Methods: This multicenter, randomized, open-label trial enrolled men and women aged ≥18 years at high risk of mpox. Participants were randomly assigned 1:1 to early- or late-vaccination groups. The primary endpoint was vaccine efficacy (VE) against mpox. Secondary endpoints included VE against severe mpox, symptoms, “take” incidence, adverse events (AEs), and immunogenicity in participants with human immunodeficiency virus (HIV). Results: In total, 570 and 565 participants were assigned to early- and late-vaccination groups, respectively, with 530 and 476 vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had HIV. No mpox cases occurred, precluding VE calculations. The take rates were 89.5% (with HIV) and 93.9% (without HIV). AEs occurred in 97.2% and 98.2% of participants with and without HIV, respectively. No fatal AEs were observed. Serious adverse events (SAEs) were observed in 2/352 (0.6%) and 3/654 (0.5%) of participants with and without HIV, respectively, of which 1 SAE causally related to vaccination occurred in a participant without HIV. Seroconversion rates for LC16m8 and MPXV were 96.2% and 69.2%, respectively, in participants with HIV, and 92.0% and 52.0%, respectively, in individuals without HIV. Conclusions: LC16m8 efficacy in mpox remains inconclusive. However, in individuals with well-controlled HIV, it was immunogenic and raised no significant safety concerns, suggesting its suitability for targeted vaccination of at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137)
- 21 February 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
Background: This randomized controlled trial provided LC16m8 pre-exposure prophylaxis to high-risk individuals to assess its efficacy for mpox prevention, safety, and immunogenicity. Methods: This multicenter, randomized, open-label trial enrolled men and women aged ≥18 years at high risk of mpox. Participants were randomly assigned 1:1 to early- or late-vaccination groups. The primary endpoint was vaccine efficacy (VE) against mpox. Secondary endpoints included VE against severe mpox, symptoms, “take” incidence, adverse events (AEs), and immunogenicity in participants with human immunodeficiency virus (HIV). Results: In total, 570 and 565 participants were assigned to early- and late-vaccination groups, respectively, with 530 and 476 vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had HIV. No mpox cases occurred, precluding VE calculations. The take rates were 89.5% (with HIV) and 93.9% (without HIV). AEs occurred in 97.2% and 98.2% of participants with and without HIV, respectively. No fatal AEs were observed. Serious adverse events (SAEs) were observed in 2/352 (0.6%) and 3/654 (0.5%) of participants with and without HIV, respectively, of which 1 SAE causally related to vaccination occurred in a participant without HIV. Seroconversion rates for LC16m8 and MPXV were 96.2% and 69.2%, respectively, in participants with HIV, and 92.0% and 52.0%, respectively, in individuals without HIV. Conclusions: LC16m8 efficacy in mpox remains inconclusive. However, in individuals with well-controlled HIV, it was immunogenic and raised no significant safety concerns, suggesting its suitability for targeted vaccination of at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137)
- Open Access
- 6 February 2025
- Published by Wiley in Journal of General and Family Medicine
- Vol. 26 (3) , 267-268
Cervical epidural abscess mimicking crowned dens syndrome
An 88‐year‐old woman was diagnosed with crowned dens syndrome. Magnetic resonance imaging showed an abscess around the odontoid process. The patient was also found to have infective endocarditis.
- 6 February 2025
- Published by Wiley in Journal of General and Family Medicine
- Vol. 26 (3) , 267-268
Open AccessCervical epidural abscess mimicking crowned dens syndrome
An 88‐year‐old woman was diagnosed with crowned dens syndrome. Magnetic resonance imaging showed an abscess around the odontoid process. The patient was also found to have infective endocarditis.